Clinical Trials Directory

Trials / Completed

CompletedNCT01418625

Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions

An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg Capsule (Reference Formulation, Wyeth Pharmaceuticals Inc., USA) Administered as the Contents of Capsule Sprinkled Over Apple Sauce in Healthy Volunteers Under Fed Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Torrent Pharmaceuticals Limited · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers

Summary

Objective: The Bioequivalence studies were performed to compare the rate and extent of release of the drug substance from the two Capsule formulations containing Venlafaxine Hydrochloride Extended-Release Capsules 150mg of Torrent Pharmaceuticals Limited and the Effexor XR® (Venlafaxine Hydrochloride) Extended-Release Capsules 150mg of Wyeth Pharmaceuticals Inc., USA. Study Design: Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg capsule (Reference formulation, Wyeth Pharmaceuticals Inc., USA) in Healthy Volunteers

Conditions

Interventions

TypeNameDescription
DRUGVenlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)

Timeline

First posted
2011-08-17
Last updated
2011-08-17

Source: ClinicalTrials.gov record NCT01418625. Inclusion in this directory is not an endorsement.